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Antibodies to citrullinated proteins, common in rheumatoid arthritis (RA) patients, are 
strongly associated to a specific set of HLA-DR alleles including HLA-DRB1*04:01, 
*04:04, and *01:01. Here, we first demonstrate that autoantibody levels toward the 
dominant citrullinated B cell epitope from α-enolase are significantly elevated in HLA-
DRB1*04:01-positive RA patients. Furthermore, we identified α-enolase-derived T cell 
epitopes and demonstrated that native and citrullinated versions of several peptides bind 
with different affinities to HLA-DRB1*04:01, *04:04, and *01:01. The citrulline residues in 
the eight identified peptides are distributed throughout the entire length of the presented 
epitopes and more specifically, localized at peptide positions p-2, p2, p4, p6, p7, p10, and 
p11. Importantly, in contrast to its native version peptide 26 (TSKGLFrAAVPSGAS), the 
HLA-DRB1*04:01-restricted citrullinated peptide Cit26 (TSKGLFcitAAVPSGAS) elicited 
significant functional T cell responses in primary cells from RA patients. Comparative 
analysis of the crystal structures of HLA-DRB1*04:01 in complex with peptide 26 or 
Cit26 demonstrated that the posttranslational modification did not alter the conformation 
of the peptide. And since citrullination is the only structural difference between the two 
complexes, this indicates that the neo-antigen Cit26 is recognized by T cells with high 
specificity to the citrulline residue.
Keywords: rheumatoid arthritis, hla-Dr4/α-enolase, neo-antigen, cD4+ T cell, autoimmunity, cytokines, crystal 
structures
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inTrODUcTiOn
Rheumatoid arthritis (RA) is a chronic inflammatory disease 
affecting approximately 0.5–1% of the population worldwide 
(1). Ever since the discovery of the genetic association of RA to a 
subset of HLA-DR alleles (2), CD4+ T cells have been considered 
as classical effector cells in RA. Furthermore, the importance of 
CD4+ T cell effector functions in RA pathogenesis is corroborated 
both by therapeutic interventions affecting adaptive immune 
responses (3, 4) and by multiple studies of polyclonal T cell 
cytokine production (5, 6). The identification of RA-associated 
antibody responses to citrullinated proteins and the genetic link 
established between the presence of such autoantibodies and 
certain HLA class II molecules (7) has directed the investiga-
tion of novel autoantigens, and thereby promoted a renaissance 
in CD4+ T cells studies, as T helper cells would be assumed to 
govern IgG responses (8). Indeed, the existence of T cell epitopes 
derived from a range of citrullinated RA-associated autoantigens 
has recently been demonstrated (9–11). A detailed understanding 
of when, where, and how tolerance is broken and citrullination-
mediated autoimmunity develops may aid toward future preven-
tive strategies.
Still all too little is known about the nature of HLA-DR-
restricted native and posttranslationally modified (PTM) T cell 
self-epitopes that are involved in the development of RA. The 
main established association between HLA class II molecules 
and RA has been correlated to the polymorphic region of the 
β-chain comprising amino acid residues 70–74 (12) that line 
the MHC-II pocket close to peptide anchor residue p4 and that 
is shared between HLA-DRB1*04:01, *04:04, and *01 alleles 
(Figure S1A in Supplementary Material). More recently the 
importance of residues 11 and 13, localized at the bottom of 
MHC-II pockets P4 and P6, respectively, for initiation of RA has 
also been described (13). Both uncharged as well as positively 
charged residues at positions 13 and 71, respectively, have been 
suggested to direct the nature of peptide anchor residues that 
are accommodated within the P4 pocket of the antigen-binding 
groove of these MHC-II molecules. To our knowledge, only one 
study has hitherto provided insights in the structural features 
of citrullinated peptides in complex with HLA-DRB1*04:01, 
*04:02, and *04:04 (14). This study demonstrated that citrul-
linated vimentin- or aggrecan-derived peptide residues bind to 
different MHC class II alleles at peptide positions p2, p4, p9, 
and/or p11 in a classical manner. In all cases, the citrullinated 
residue at position p4 could be accommodated within the 
positively charged pocket of the HLA-DRB1*04:01 and *04:04 
alleles, and emerged slightly from the peptide-binding cleft in 
order to interact with presumptive T cell receptors (TCRs). 
In contrast, the corresponding negatively charged P4 pocket 
in the RA-resistant DRB1*04:02 allele disallowed binding of 
citrullinated epitopes. Thus citrullination of different peptides 
resulted in the formation of neo-antigens.
In the present study, we focused on citrullinated α-enolase, 
one of the candidate antigens toward which a large number of 
RA patients develop autoantibodies. The main B cell epitope 
in α-enolase, denoted CEP-1, resides between amino acids 5 
and 21 (15). Importantly, CEP-1 autoantibodies are highly 
associated with the shared epitope (SE) HLA-DR alleles (16), 
including HLA-DRB1*01, *04:01, and *04:04, which are the 
most common RA-associated alleles in the patient cohort 
analyzed within  this study. An unbiased screening of partially 
overlapping 15 amino acid long peptides, covering the entire 
α-enolase protein, allowed us to identify a set of potential T 
cell epitopes that bind to these three RA-associated-HLA-DR 
alleles. We demonstrate that T cell responses were significantly 
enhanced toward citrullinated epitopes in HLA-DRB1*04:01-
positive RA patients compared to *01 and *04:04 patients. 
The most striking responses were established for peptide 26, 
where only the citrullinated version Cit26 elicited statistically 
significant T  cell responses. We assessed the structural basis 
underlying these functional differences by determining and 
comparing the crystal structures of HLA-DRB1*04:01 in 
complex with the native and citrullinated versions of peptide 
26. Our results reveal that the posttranslational modification 
does not alter the conformation of the citrullinated peptide 
Cit26 compared to the native peptide 26. The side chain of the 
citrulline residue at position p2 in Cit26 projects toward the 
solvent, fully available for interactions with TCRs. This single 
significant difference between the two complexes suggests that 
the citrullinated neo-antigen Cit26 may bypass T cell tolerance 
and provoke undesired responses from T cells with high and 
possibly unique specificity to the citrulline residue.
MaTerials anD MeThODs
autoantibody Detection in serum from a 
large cohort of ra Patients
A total of 2934 RA patients from the Epidemiological investiga-
tions in rheumatoid arthritis (EIRA) cohort (17) were investigated 
with the Phadia ISAC microarray (18) and analyzed for antibod-
ies against the immunodominant α-enolase peptide CEP-1. After 
exclusion of samples reacting with the chip background or with 
streptavidin, technically unobjectionable results were obtained 
from 2858 RA patients with information on HLA-DRB1 alleles. 
Of these patients, 1396 had one single HLA-DRB1 SE allele with 
426 being HLA-DRB1*01, 422 *04:01, and 134 *04:04. The cutoff 
was set at the 98th percentile for a control group consisting of 578 
EIRA healthy controls.
Patients and cell samples
Twenty-six HLA-DRB1*04:01, HLA-DRB1*04:04, and HLA-
DRB1*01 RA patients were included in this study (Table S1 in 
Supplementary Material). All subjects were recruited under 
the auspices of the Karolinska University Hospital/Karolinska 
Institutet Arthritis Research Program. Informed consent 
was obtained from all subjects under protocols approved by 
the Karolinska Hospital Ethical Review Board. Three HLA-
DRB1*04:01-positive blood donors were recruited from the 
Uppsala Bioresource as healthy controls for this study. Peripheral 
blood mononuclear cells (PBMCs) were obtained from heparin-
ized blood by centrifugation over Ficoll-Hypaque (GE Healthcare) 
gradients. PBMCs were cryopreserved in liquid nitrogen in 10% 
DMSO and 90% heat-inactivated fetal bovine serum.
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Mass spectrometry analyses of 
citrullinated recombinant α-enolase
Recombinant human α-enolase was citrullinated for 2 h at 50°C 
at a concentration of 1  mg/ml in PAD buffer (100  mM Tris, 
10 mM CaCl2, 5 mM DTT, pH 7.6) using 2 U/mg protein of rabbit 
skeletal muscle PAD2 enzyme (Sigma-Aldrich). The reaction was 
stopped by the addition of EDTA to a concentration of 20 mM, 
followed by extensive dialysis to calcium-free PBS. Also, 10 μg of 
the citrullinated enolase were reduced, alkylated, and digested 
in-solution as previously described (19). After zip tipping (Merck 
Millipore Ltd., Republic of Ireland), an amount corresponding 
to 2 pmol prior precipitation and digestion was separated using 
on-line nLC–MS/MS (RP C18) and analyzed on a Q Exactive 
MS (Thermo Fisher Scientific, Germany). A 40-min gradient of 
buffer A and B (A: 1% formic acid in water; B: 1% formic acid 
in acetonitrile) was used for the separation: 5–30% B for 35 min, 
followed by 30–95% B for 5 min. The flow rate was 300 nl/min. 
Mass lists were extracted using Raw2MGF v2.1.3 (20) and used 
to search a concatenated version of the SwissProt database 
(2013/4) using the Mascot search engine v2.3.02 (Matrix Science 
Ltd., London, UK). The following parameters were used for the 
database searching: tryptic digestion (with a maximum of two 
miscleavages); carbamidomethylation (C) as fixed modification; 
oxidation (M), pyroglutamate (Q), deamidation (N/Q), and 
citrullination (R) as variable modifications; 10 ppm as precursor 
tolerance and 0.1 Da as fragment tolerance. Spectra identifying 
citrullinated peptides were validated manually by verifying 
that the precursor mass was correctly assigned, and that the 
modified site was consistent with observed mass shifts in the 
fragment ions.
hla-DrB1 Peptide-Binding assays
Stepwise binding analysis of 15-mer peptides derived from both 
native and citrullinated α-enolase to HLA-DRB1*01, *04:01, and 
*04:04 was performed using the ProImmune Class II Reveal assay 
(ProImmune, Oxford, UK). Relevant peptides were thereafter 
synthesized by GenScript (Piscataway, NJ, USA) and used for 
competition peptide-binding assays. Epitopes were incubated 
in increasing concentrations in the presence of plate-bound 
HLA-DRB1*01, *04:01, or *04:04 and 0.02 μM of the biotinylated 
competitor epitopes HA306–318 (PKYVKQNTLKLAT) for HLA-
DRB1*04:01 and *01:01, and GAD65270–285 (LPRLIAFTSEHSHFS) 
for HLA-DRB1*04:04 (21). Finally, peptide-binding affinity to 
the three different HLA alleles was assessed in direct binding 
assays in which N-terminally biotinylated epitopes (GenScript, 
Piscataway, NJ, USA) were incubated at concentrations from 5 to 
0.05 μM with plate-bound relevant HLA-DRB1 molecules in the 
absence of a competitor peptide (22). The inflection point of the 
binding curve of a known binding epitope was used as a cutoff to 
separate weakly binding epitopes from background.
Functional cellular assays
Functional T cell assays were performed as previously described 
(9). PBMCs were cultured for 5 days in the presence of 20 μg/ml 
peptides at a total cell concentration of 1 × 106 cells/well in flat 
bottom 96-well plates in RPMI 1640 supplemented with 2 mM 
l-glutamine, 100  U/ml penicillin, 100  μg/ml streptomycin, 
10  mM HEPES, and 10% pooled human serum. PBMCs were 
restimulated with peptides and anti-CD28 (BioLegend) on day 5 
for 6 h with 5 μg/ml Brefeldin A (Sigma-Aldrich) being added for 
the last 4 h. Restimulated cells were treated with LIVE/DEAD® 
Fixable Green Dead Cell Stain (Invitrogen) and thereafter stained 
for surface expression of CD3 (BioLegend), CD4, and CD14 (BD 
Biosciences). Cells were then stained intracellularly for IFN-γ and 
IL-17A (BioLegend) as well as CD154 (CD40L) (BD Biosciences) 
expression using the Cytofix/Cytoperm fixation and permeabi-
lization solution kit (BD Biosciences). Samples were run on a 
CyAn™ ADP Analyzer (Beckman Coulter), and data were ana-
lyzed using FlowJo software, version 7.5.1 or higher (Tree Star). 
The gating strategy is depicted in Figure S2 in Supplementary 
Material. In some experiments, blocking antibodies for HLA-DR 
(clone L243), -DP (clone B7/21), and -DQ (clone SPLV3), all 
obtained from the Tetramer Core Facility (BRI, Seattle, WA, 
USA), were added to the cultures.
cytokine Detection in supernatants
A bead-based multiplex cytokine assay was custom-designed by 
Invitrogen for simultaneous detection of IL-10, IL-13, IL-17A, 
IL-17F, TNF-α, and IFN-γ on a Luminex platform. Supernatants 
were collected at day 5 and stored at −80°C until used. Supernatants 
from RA patients were analyzed using the Luminex 100 system 
according to the manufacturer’s instructions.
Production and isolation of hla-
DrB1*04:01 in complex with Peptides 26 
and cit26
Peptides 26 and Cit26 were purchased at >95% purity from 
GenScript (Piscataway, NJ, USA). The extracellular domains of 
the HLA-DRB1*04:01 α- and β-chains with an acidic and basic 
leucine zipper, respectively, as well as a C-terminal hexahistidine 
tag were expressed separately in E. coli BL21 (DE3) STAR cells 
(Novagen). Inclusion bodies, dissolved in 8M urea, 50  mM 
Tris–HCl (pH 8) were purified on a HiTrapQ HP anion exchange 
column (GE Healthcare). The purified α- and β-chains were 
diluted to a final concentration of 2 mg/ml each in a refolding 
solution containing 50 mM Tris–Citrate buffer pH 7.5, 25% (w/v) 
glycerol, 0.01% Pluriol F68, and 5 μM peptide. HLA-DRB1*04:01 
in complex with either peptides 26 or Cit26, obtained after 72 h 
in  vitro room temperature refolding, were concentrated using 
a 10-kDa cutoff Vivaspin Turbo 15 (Sartorius) and thereafter 
dialyzed against 25 mM Tris–HCl, pH 8.0. Both complexes were 
isolated using anion exchange on a Mono Q5/50 column followed 
by size-exclusion chromatography on a Superdex 200 column 
(GE Healthcare). The monomeric MHC-II/peptide complexes 
were concentrated to 1 mg/ml, subjected to thrombin cleavage in 
order to remove the leucine zippers and further purified using a 
HiTrap Chelating HP column (GE Healthcare). The flow-through 
was pooled, concentrated using a 10-kDa cutoff Vivaspin Turbo 
15 (Sartorius), and further purified on a Superdex 200 column. 
Fractions containing monomeric MHC-II/peptide complexes 
were concentrated using a 10-kDa cutoff Vivaspin Turbo 4 
(Sartorius) to 10 mg/ml.
FigUre 1 | The amount of autoantibodies toward ceP-1 in citrullinated α-enolase is significantly enhanced in hla-DrB1*04:01-positive subjects 
compared to *01- and *04:04-positive subjects. (a) Frequency of RA patients positive for anti-CEP-1 antibodies among HLA-DRB1*04:01-positive (n = 228 out 
of 422), *04:04-positive (60/134), and *01-positive individuals (149/426). The cutoff for the ELISA assay was set at the 98th percentile based on a control group 
consisting of 578 EIRA healthy controls. For overall comparison of the frequency of anti-CEP-1 positivity in patients carrying a certain genotype, we used Pearson’s 
chi-squared test. Four asterisks correspond to 0.0001. (B) Levels of anti-CEP-1 antibodies in HLA-DRB1*04:01-, *04:04-, and *01-positive RA patients. Cutoff is set 
at 83.08 AU. Unpaired Student’s t-test was used to compare anti-CEP-1 antibody levels. Four asterisks correspond to 0.0001.
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crystallization and structure 
Determination of the hla-DrB1*04:01/26 
and hla-DrB1*04:01/cit26 complexes
Crystals of the HLA-DRB1*04:01/26 and HLA-DRB1*04:01/Cit26 
complexes were obtained using the hanging-drop vapor diffusion 
method at 20°C. Protein solution and a mother liquor of 100 mM 
sodium malonate, pH 4.0, 12–18% (vol/vol) PEG3350 were mixed 
at a 1:1 ratio and equilibrated against 1 ml of mother solution. 
Rod-like crystals typically grew within 2–6 days. Crystals were 
flash frozen in liquid nitrogen after soaking in 35% PEG 3350. 
X-ray diffraction data for the HLA-DRB1*04:01/Cit26 complex 
were collected at the ID23-1, European Synchrotron Research 
Facility, and for the HLA-DRB1*04:01/26 complex at the beam-
line BL14-1, Helmholtz-Zentrum Berlin, and processed using the 
programs XDS (23, 24) and XDSAPP (25). The crystal structures 
were determined by molecular replacement using the program 
Phaser (26) and a HLA-DRB1*04:01/peptide complex (PDB code 
4MCY) (14) with the peptide omitted and subsequently refined 
using Refmac5 and iterations of manual refinement using Coot 
(27). The crystal structures were validated using MOLPROBITY 
(Table 3) (28). The coordinates and structural factors of the crys-
tal structures of the HLA-DRB1*04:01 in complex with peptides 
26 and Cit26 have been deposited to the Protein Data Bank under 
accession codes 5LAX and 5JLZ, respectively.
statistical analysis
Statistical analyses were performed using Prism 6 software (Graph 
Pad, San Diego, CA, USA). If not stated otherwise, mean with SD 
is depicted. Detailed information on statistical tests can be found 
in the figure legends. P values less than 0.05 were considered 
significant and depicted with an asterisk.
resUlTs
autoantibody levels toward citrullinated 
α-enolase are significantly enhanced 
in hla-DrB1*04:01-Positive compared  
to hla-DrB1*01- or *04:04-Positive ra 
Patients
We hypothesized that different RA-associated HLA-DR alleles 
could bias citrulline-based antibody-mediated autoimmunity 
and therefore first investigated the prevalence of autoantibodies 
toward the major B cell epitope CEP-1 on citrullinated α-enolase. 
Based on the EIRA cohort (17), 982 RA patients who carried one 
copy of either HLA-DRB1*04:01, *04:04, or *01 and with avail-
able CEP-1 data were identified. This initial analysis revealed 
significantly higher frequencies and levels of antibodies specific 
to CEP-1 in HLA-DRB1*04:01 patients compared to HLA-
DRB1*04:04 and *01 patients (Figure 1).
identification of novel hla-Dr-restricted 
α-enolase-Derived T cell epitopes
We first performed an unbiased binding screen using both native 
and citrullinated 15-mer peptides overlapping by five amino acid 
residues, covering the entire protein (data not shown). This assay, 
the so-called ProImmune Class II Reveal assay (ProImmune, 
Oxford, UK), provided initial indications for binding to HLA-
DRB1*01, *04:01, and *04:04 (Table S2 in Supplementary 
Material). The peptides with the highest scores were selected 
for further analysis (Table  1). The crystal structure of human 
α-enolase homodimer (PDB entry 3B97) (30) allowed us to 
evaluate the propensity of all arginine residues to be citrullinated. 
TaBle 1 | sequence of candidate peptides, aligned according to 
the predicted position in the groove of hla-DrB1*04:01, in vitro 
citrullination.
Peptide ID Amino acid 
numbers
Sequence/pockets
1  4 6  9
In vitro 
citrullination
1/Cit1 1–15 MSI  LKIHAREIF DSR 9, 15
11/Cit11 11–25 I FDSRGNPTV EDVLF 15
26/Cit26 26–40 TSKGL FRAAVPSGA S n.d.
56/Cit56 56–70 RY MGKGVSKAV EHIN 56
171/Cit171 171–185 LP VGAANFREA MRIG 183
241/Cit241 241–255 VIG MDVAASEFF RSG n.d.
326/Cit326 326–340 KR IAKAVNEKS CNCL n.d.
420/Cit420 420–434 KAK FAGRNFRNP LAK 426, 429
n.d., not detected, i.e., peptides were not found, arg vs. cit status could thus not be 
determined.
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All the peptides identified through the first screening were 
exposed to the solvent (Figure S1B in Supplementary Material). 
Furthermore, mass spectrometry analyses of in vitro citrullinated 
recombinant α-enolase protein revealed that at least five of the 
identified epitopes (peptides 1, 11, 56, 171, and 420) were citrul-
linated (Table 1), while the native forms of the three remaining 
peptides (26, 241, and 326) could not be identified and therefore 
their propensity for citrullination could not be assessed.
The sequences of all the identified peptides were aligned 
according to the HLA-DR pocket preferences at P1, P4, P6, 
and P9, indicating that citrulline residues can be positioned in 
different pockets within the clefts of HLA-DRB1*04:01, *04:04, 
and *01, or alternatively can protrude toward TCRs (Table  1). 
It should be noted that only peptides 11 and 420 comprised 
arginine/citrulline residues that could act as anchoring positions 
within pocket P4. The arginine/citrulline residues in peptides 
1, 171, and 420 may either interact with pockets P6 or P7, or 
protrude out of the HLA cleft. In all the other cases, the arginine/
citrulline residues localized at peptide positions p-2, p-1, p2, p10, 
p11, and p12 are predicted to protrude out of the cleft, readily 
available for interactions with TCRs (Table 1).
native and citrullinated  
α-enolase-Derived Peptides 
Bind with Different affinities to  
hla-DrB1*04:01, *04:04, and *01:01
The HLA-DR binding capacity of the identified peptides was 
assessed through in  vitro competition binding assays in which 
native and citrullinated candidate epitopes were tested for their 
capacity to displace an established reference peptide (Figure 2; 
Table  2). We decided to make use of HLA-DRB1*01:01 as a 
representative model for HLA-DRB1*01. Our analyses revealed 
that both the native and citrullinated versions of peptides 26 and 
241 were able to efficiently compete with the reference peptide in 
the context of HLA-DRB1*04:01, *04:04, and *01:01. In contrast, 
neither native nor citrullinated peptides 56 and 171 could dis-
place the reference peptide in any of the three MHC class II mol-
ecules. Furthermore, both versions of peptide 420 were unable 
to compete with the reference peptide in HLA-DRB1*04:01 and 
*01:01 but could weakly displace the HLA-DRB1*04:04 reference 
peptide.
Clear differences were established for the capacity of 1/Cit1, 
11/Cit11, and 326/Cit326 to compete with reference peptides in 
the context of either all three or only one of the MHC class II 
molecules. While both 326 and Cit326 efficiently displaced the 
reference peptide in HLA-DRB1*04:01 and *04:04, they were not 
able to do so with HLA-DRB1*01:01. Interestingly, citrullina-
tion of peptide 11 significantly enhanced competition efficiency 
in the context of all three MHC alleles. In contrast, the native 
version could not compete in HLA-DRB1*01:01 and *04:01 
and was able to only weakly compete the reference peptide in 
HLA-DRB1*04:04. Finally, a converse situation was observed 
for peptide 1 with HLA-DRB1*01:01, where citrullination sig-
nificantly reduced the capacity of Cit1 to compete. Neither native 
nor citrullinated version of this peptide demonstrated significant 
competition with the reference peptide in the context of HLA-
DRB1*04:01 and *04:04.
It is probable that the binding thresholds within our competi-
tion assays exceed the requirements for weakly binding peptides 
that still can be relevant functionally. Indeed, an example of 
a peptide that appears negative in MHC binding assays, but 
still provides functional T cell responses, has been previously 
identified (22). We therefore assessed the direct binding of 
biotinylated versions of all the native and citrullinated peptides 
that did not or did only very weakly displace reference peptides 
in our competition assays, to plate-bound HLA-DRB1*04:01, 
*04:04, and *01:01 (Figure 3). Specific N-terminal biotinylation 
of peptides via ε-aminocaproic acid linker prevents modification 
of lysine residues within the peptides and is thus not expected 
to affect peptide–MHC interaction. No significant binding could 
be confirmed for native or citrullinated versions of peptides 
56 and 171. Conversely, although the native and citrullinated 
versions of peptide 326 could not displace the reference peptide 
in HLA-DRB1*01:01, both 326 and Cit326 bound well to this 
MHC allele in direct binding assays (Figure 3; Table 2). Also in 
contrast to the competition assay results, both versions of peptide 
420 bound well to all three MHC class II alleles, however, always 
with a significantly reduced binding capacity for the citrullinated 
version compared to the native form. Finally, the direct binding 
assays confirmed that both forms of peptide 1 do not bind to 
HLA-DRB1*04:01 and bind only weakly to HLA-DRB1*01:01 
(Figure  3; Table  2).
in contrast to native Versions, several 
hla-DrB1*04:01-restricted citrullinated 
Peptides elicit Functional T cell 
responses in Primary cells from 
ra Patients
Primary cells from HLA-typed RA patients (Table S1 in 
Supplementary Material) were screened for T cell activation, 
assessed by CD40L upregulation as well as intracellular cytokine 
staining (ICS), following in  vitro stimulation with native or 
citrullinated variants of the identified peptides. As expected, 
cytokine production is largely confined to the CD40L+ T cell 
subset (Figure S2 in Supplementary Material). IL-17A and/
or IFN-γ production were observed in conjunction with a set 
of native and/or citrullinated α-enolase peptide stimulations, 
FigUre 2 | competition binding assays demonstrate the differential capacity of native and citrullinated α-enolase-derived peptides to bind to 
hla-DrB1*04:01, *04:04, and *01:01. The upper, middle, and lower panels present the results from the competition binding assays for all the eight identified 
α-enolase-derived peptides to (a) HLA-DRB1*04:01, (B) HLA-DRB1*04:04, and (c) HLA-DRB1*01:01, respectively. The curves for the reference peptide, native, 
and citrullinated α-enolase peptides are displayed in dashed, gray, and black lines, respectively. All plots are arranged according to the order of appearance in 
Table 2.
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FigUre 3 | Direct binding assays reveal the capacity of specific 
α-enolase-derived peptides to bind to the three different Mhc alleles. 
Direct binding assays were performed for peptide pairs that did not bind or 
bound poorly to the three different MHC alleles in the competition binding 
assays. The point of inflection in the curve for the reference peptide was 
defined as the binding threshold reference point. Thus, any peptide that did 
not reach or barely passed this level was assessed as non-binding. Curves 
for the reference peptide, the non-binding, and binding peptides are 
displayed in dashed, gray, and black lines, respectively.
TaBle 2 | results of the competition and direct binding assays.
ic50 (μM)
Peptide *04:01 *04:04 *01:01
26 4.0 0.5 1.4
cit26 1.5 0.5 1.9
241 2 0.5 35
cit241 2.5 0.2 42
56 – – –
cit56 – – –
171 – – –
cit171 – >50 –
420 >50 25 >50
cit420 >50 28 >50
326 1.7a 0.7 >50
cit326 1.9a 0.7 >50
11 >50a >50 –
cit11 2.2a 1.7 25
1 – >50 3.5
cit1 – >50 >50
>50, weak binding confirmed in direct binding assay.
aPublished in Ref. (29).
–, No binding detected.
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especially in the context of HLA-DRB1*04:01 (Figure 4; Figure 
S3 in Supplementary Material). Notably, T cell responses in 
HLA-DRB1*04:01-positive patient samples were significantly 
increased toward the citrullinated peptide Cit26 compared to 
its native counterpart (Figure  4A). Although not statistically 
significant, similar trends were observed for peptides Cit11, 
Cit56, Cit241, and Cit420 compared to their native counterparts. 
A similar trend was also observed in HLA-DRB1*01-positive 
patient samples with peptide 420. In contrast, the citrullination 
of peptides 1 and 326 decreased T cell responses in HLA-
DRB1*04:01-positive patients (Figure 4A).
Next, we assessed T cell responses elicited by the identified 
native or citrullinated peptides in HLA-DRB1*04:01-positive 
healthy controls. In contrast to RA patients, most T cell responses 
were comparable to the unstimulated threshold value. Thus, 
our results indicate that the T cell responses toward HLA-
DRB1*04:01-restricted citrullinated peptides are more robust and 
pro-inflammatory in RA patients compared to healthy controls 
(Figure 4; Figure S3 in Supplementary Material). Furthermore, 
to ensure that the observed peptide responses were indeed 
restricted by HLA-DR alleles and not influenced by accompany-
ing HLA-DP or HLA-DQ alleles, we also performed stimulation 
experiments where blocking antibodies toward the different HLA 
class alleles were included. In contrast to HLA-DP- or HLA-DQ-
blocking antibodies, only HLA-DR-blocking antibodies were 
able to ablate responses to the stimulatory peptides (Figure S4 in 
Supplementary Material).
In conclusion, the citrullinated versions of peptides 26, 
56, and 241 result in enhanced T cell responses in HLA-
DRB1*04:01-positive patients. In line with these findings, 
analysis of a broad cytokine panel in supernatants from 
cultured PBMCs following stimulation with either native or 
citrullinated peptides also revealed strong responses toward 
Cit26, Cit56, and Cit241 compared to the native peptide forms 
(Figure S5 in Supplementary Material).
citrullination at Peptide Position 2 Does 
not alter the conformation of cit26 
compared to the native Peptide 26 and 
results in the Formation of a neo-antigen
In order to assess the structural bases that underlie stronger 
T cell responses toward HLA-DRB1*04:01 in complex with the 
FigUre 4 | cytokine production in cultured primary cells from hla-DrB1*04:01-positive ra patients is significantly increased to the citrullinated 
peptide cit26 compared to the native peptide 26.  
(Continued)
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(a) Summary of intracellular flow cytometry stainings for IFN-γ following 5 days of culture of RA patient samples with or without peptide stimulation. Single patient 
values are indicated by dots. The mean with SD is depicted for unstimulated cultures (light gray) as well as cultures stimulated with the positive control peptide HA 
(striped bar) and the eight peptide pairs (light gray bars: native versions; dark gray bars: citrullinated versions), respectively. Statistical analysis was performed using 
Wilcoxon signed rank test when comparing levels of IFN-γ production in PBMCs stimulated with native or citrullinated peptides. Chauvenet’s criterion was used to 
exclude possible experimental outliers; however, all data points were calculated to be in range and thus kept in the analysis. Number of patient samples included for 
HLA-DRB1*04:01 is nine with eight of these used for peptide pairs 26/Cit26, 56/Cit56, and 241/Cit241, six for peptide pairs 1/Cit1 and 420/Cit420, and five for 11/
Cit11, 171/Cit171, and 326/Cit326. For HLA-DRB1*04:04, we used five patient samples in total, with peptide pairs 1/Cit1, 56/Cit56, 171/Cit171, 241/Cit241, 326/
Cit326, and 420/Cit420 being tested in three of those and peptide pair 11/Cit11 in two. Three HLA-DRB1*01 patient samples were used for all peptide pairs except 
for 1/Cit1 and 171/Cit171, where only two samples were tested. (B) Intracellular flow cytometry stainings for IFN-γ after 5 days of culture of three HLA-DRB1*04:01 
healthy control samples with or without peptide stimulation do not show the same level and breadth of response to citrullinated peptides as HLA-DRB1*04:01-
positive RA patients. Besides single values, the mean with SD is depicted for unstimulated cultures (light gray) as well as cultures stimulated with the positive control 
peptide HA (striped bar) and the eight peptide pairs (light gray bars: native versions; dark gray bars: citrullinated versions), respectively. Number of samples tested 
was three for all the peptide pairs except for peptide pair 1/Cit1 and 171/Cit171 where only two samples were tested.
FigUre 4 | continued
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PTM peptide Cit26 compared to the native α-enolase epitope 
26 in RA patients, we determined the crystal structures of HLA-
DRB1*04:01 in complex peptides 26 and Cit26 at 2.6 and 2.0 Å 
resolution, respectively (Figure 5; Table 3). Both peptides take 
prototypic conformations, extending throughout the length 
of the binding cleft of HLA-DRB1*04:01, using residues p31F, 
p34A, p36P, and p39A to anchor in pockets P1, P4, P6, and P9, 
respectively. Comparative analysis of both complexes reveals 
that all HLA-DRB1*04:01 and the peptide residues keep exactly 
the same conformations. The only difference between the two 
crystal structures is the side chain of the citrullinated residue 
p32Cit in Cit26, which similarly to the arginine residue in HLA-
DRB1*04:01/26, protrudes toward the solvent readily available 
for interactions with TCRs. Thus, citrullination of peptide 26 
creates a neo-antigen that could select for an entirely different 
autoreactive T cell repertoire, with most probably high specificity 
to the citrulline residue in Cit26.
DiscUssiOn
Using the HLA-DRB1*01:01, *04:01, and *04:04 alleles that are 
all genetically associated with RA and commonly found in our 
cohort of RA patients, we initiated this study by demonstrat-
ing that the autoantibody levels toward citrullinated α-enolase 
are significantly increased in HLA-DRB1*04:01-positive 
RA patients compared to *01 and *04:04 RA patients. These 
results provided us with a first indication that T cell responses 
in HLA-DRB1*04:01-positive RA patients could be stronger 
toward α-enolase-derived peptides compared to *01 and *04:04 
RA patients. Covering the entire protein, we identified eight 
15-mer peptides that tentatively could be presented by HLA-DR 
(Table  1). Only two of the identified epitopes comprised an 
arginine/citrulline residue that occupies the HLA class II pocket 
P4 (peptides 11/cit11 and 420/Cit420). In all the remaining 
identified peptides, the arginine/citrulline residues localized 
at positions p-2, p-1, p2, p10, p11, and p12 were predicted by 
molecular modeling to protrude out of the cleft, readily available 
for interactions with TCRs (data not shown). Thus, our results 
indicate that citrullination can occur on virtually any position 
in HLA class II-restricted peptides. Peptides able to bind to the 
RA-associated HLA-DR alleles are candidates for HLA-DR-
tetramer approaches where the autoreactive T cell repertoire can 
be assessed in patient material. Interestingly, we have previously 
reported the presence of tetramer-positive T cells to two of these 
α-enolase epitopes (cit11 and cit326) in the context of HLA-
DRB1*04:01-positive healthy subjects and RA patients (29).
We could also demonstrate diverse peptide preferences for 
the three different HLA-DR alleles, and that citrullination can 
enhance or reduce the binding affinity of peptides to MHC-II 
molecules. For HLA-DRB1*04:04, the relatively smaller size of 
the P1 pocket may hinder binding of some of the epitopes 
favored by HLA-DRB1*04:01. In contrast, pockets P4, P6, and 
P7 in HLA-DRB1*04:04 comprise different amino acid residues 
that alter the size (but not the charge) of the pockets (16). Still, 
we cannot fully explain why the functional bias toward citrul-
linated peptides was more prominent in the HLA-DRB1*04:01 
setting compared to the two other alleles. Recently, it has been 
demonstrated that the genetic association to amino acids 11, 71, 
and 74 in the HLA-DRB1 chain correlates with disease severity 
in HLA-DRB1*04:01- followed by *04:04-positive RA patients 
(31). Of note, in the present study, we have actively excluded 
patients carrying more than one copy of the RA-associated 
HLA-DRB1 alleles.
Native and citrullinated versions of all the identified α-enolase-
derived peptides were tested for their capacity to elicit functional 
T cell responses. Significant citrulline-dependent responses 
were confirmed only for peptide 26 (TSKGLFRAAVPSGAS). 
Interestingly, both the native and citrullinated versions of 
peptide 26 bound equally well to both HLA-DRB1*04:04 and 
HLA-DRB1*01:01. In contrast, a small but significant increase in 
affinity to HLA-DRB1*04:01 was measured for Cit26 compared 
to 26. Comparative analyses of the crystal structures of HLA-
DRB1*04:01/26 and HLA-DRB1*04:01/Cit26 demonstrated that 
the only structural difference between the two MHC-II/peptide 
complexes was the modification from arginine to citrulline at 
peptide position p2. The structures reveal that both the arginine 
or the citrulline project readily toward the solvent, with the tip 
of their side chains localized very close to the central part of the 
presented peptides and thus fully available for interactions with 
CDR3s, the most sensitive and specific regions of TCRs. Our 
structural analysis also indicates that this singular posttransla-
tional modification creates a neo-antigen that may thus select for 
a repertoire of T cells with high specificity to the citrulline residue 
in Cit26. Thus, we hypothesize here that T cell subsets that have 
not been eliminated during negative selection could be selected 
through citrullination of peptide 26.
FigUre 5 | The crystal structures of hla-DrB1*04:01/26 and hla-DrB1*04:01/cit26 reveal how peptide citrullination creates a neo-antigen that 
may select for a new T cell repertoire. (a) The 2Fo-Fc electron density maps of peptides 26 (left) and Cit26 (right) bound to HLA-DRB1*04:01 contoured at 
1.0 σ allow for unambiguous positioning of all side chains. The peptides are depicted with their N and C termini to the left and right, respectively, illustrating the 
main anchor positions by vertical arrows. Residues p31F, p34A, p36P, and p39A are buried in pockets P1, P4, P6, and P9, respectively, within the HLA-
DRB1*04:01 peptide-binding cleft. Residues p30L, p32R/Cit, and p35V are accessible for interactions with TCRs. Importantly, both residues p32R and p32Cit in 
HLA-DRB1*04:01/26 and HLA-DRB1*04:01/Cit26 are extended toward the solvent and may therefore represent a key interaction contact with TCRs. Carbon, 
nitrogen, and oxygen atoms are in yellow, blue, and red, respectively. (B) Peptides 26 (left) and Cit26 (right) are represented as stick models, while HLA-
DRB1*04:01 is represented by its surface (viewed from above). Negatively and positively charged regions of the MHC-II surface are given in red and blue, 
respectively. The pockets permitting binding of different sections of the peptides are displayed. (c) Electrostatic potential representation of the surfaces of the 
HLA-DRB1*04:01/26 and the HLA-DRB1*04:01/Cit26 complexes (left and right, respectively) reveal that the positive charges from the side chain of the arginine 
residue in peptide 26 are abrogated upon substitution to a citrulline residue in peptide Cit26.
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TaBle 3 | Data collection and refinement statistics of the crystal structure 
of DrB1*04:01 in complex with α-enolase peptide 26–40 with citrulline-32 
or arginine-32.
citrulline 26–40 arginine 26–40
Data collection
Beamline ID23-1, ESRF BL14-1, BESSY
Wavelength (Å) 0.976 0.918
Space group P212121 P212121
a (Å), b (Å), c (Å) 69.4, 73.8, 145.4 69.2, 73.5, 144.6
Resolution (Å) 47.76–1.99 (2.05–1.99) 48.2–2.6 (2.75–2.6)
No. of observed reflections 274,263 138,347
No. of unique reflections 51,357 23,329
Multiplicity 5.3 5.9
Completeness (%) 99.1 (96.8) 99.6 (98.8)
aRmeas (%) 11.3 (69.8) 21.8 (98.8)
1/σ(I) 9.9 (2.1) 7.8 (1.8)
CC (1/2) (%) 99.7 (84.9) 98.9 (63.7)
Wilson B-value (Å2) 38.3 38.6
refinement statistics
Resolution of data (Å) 47.76–1.99 47.56–2.6
bRcryst (%) 20.6 19.1
cRfree (%) 24.3 27.0
No. of protein atoms 6134 6112
No. of peptide atoms 198 190
Water molecules 366 266
No. of malonate atoms 7 7
rmsd from ideal geometry
Bond lengths (Å) 0.014 0.013
Bond angles (°) 1.612 1.614
ramachandran plot (%)
Residues in preferred regions 97.0 96.4
Residues in allowed regions 3.0 3.3
Outliers 0 0.3




















 redundancy independent R-factor (intensities) (28).
bRcryst = Σ||Fo| − |Fc||/Σ|Fo|, where |Fo| and |Fc| are the observed and calculated structure 
factor amplitudes of a particular reflection, and the summation is over 95% of the 
reflections in the specified resolution range. The remaining ~5% of the reflections were 
randomly selected (test set) before the structure refinement and not included in the 
structure refinement.
cRfree was calculated over these reflections using the same equation as for Rcryst.
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Citrulline autoimmunity is a well-recognized feature of 
ACPA-positive RA. Studies of autoantibodies have made it clear 
that several modified proteins are recognized. It remains to be 
established if all these autoantibody responses are dependent on 
CD4+ T cell help. In this context, we are fully aware that α-enolase 
represents only one of several RA candidate autoantigens that are 
abundantly expressed in the rheumatic joint (32–35), but our 
study points to the importance of carefully selecting the studied 
T cell epitopes in the context of the HLA-DR alleles that are car-
ried by patients in different cohorts and their validation through 
functional T cell assays. Hopefully, this peptide will be useful for 
immuno-monitoring studies of RA in conjunction with other 
validated T cell epitopes.
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